Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study

Y. Ikeda, M. Kikuchi, H. Murakami, K. Satoh, Mitsuru Murata, K. Watanabe, Y. Ando

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

A randomized double-blind cross-over study was conducted to determine the inhibitory effects of acetylsalicylic acid (ASA), ticlopidine (TP) and cilostazol (OPC-13013; in the following briefly called CS), a new antithrombotic agent on platelet functions ex vivo. Nine patients with cerebral thrombosis were enrolled in this study. Patients were given each of the three drugs for one week in a complete cross-over design according to a randomization schedule, followed by a wash-out period with a placebo for one week. It was found that CS and TP significantly inhibited platelet aggregation induced by ADP. Collagen- and arachidonic acid-induced platelet aggregation was all inhibited by CS, TP and ASA. Duncan's multiple range test to compare the anti-platelet effects of the three drugs revealed that: CS > ASA and TP > ASA in inhibiting ADP-induced platelet aggregation and CS > TP and ASA > TP in inhibiting arachidonic acid-induced platelet aggregation. These results may suggest that CS is superior to ASA and TP in inhibiting platelet aggregation ex vivo.

Original languageEnglish
Pages (from-to)563-566
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume37
Issue number5
Publication statusPublished - 1987
Externally publishedYes

Fingerprint

Ticlopidine
Platelets
Cross-Over Studies
Aspirin
Blood Platelets
Platelet Aggregation
Agglomeration
Arachidonic Acid
Adenosine Diphosphate
Intracranial Thrombosis
Fibrinolytic Agents
Random Allocation
cilostazol
Pharmaceutical Preparations
Appointments and Schedules
Collagen
Placebos

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology

Cite this

Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. / Ikeda, Y.; Kikuchi, M.; Murakami, H.; Satoh, K.; Murata, Mitsuru; Watanabe, K.; Ando, Y.

In: Arzneimittel-Forschung/Drug Research, Vol. 37, No. 5, 1987, p. 563-566.

Research output: Contribution to journalArticle

@article{3bb3ad9e62ee4cebb153ab7c7590e225,
title = "Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study",
abstract = "A randomized double-blind cross-over study was conducted to determine the inhibitory effects of acetylsalicylic acid (ASA), ticlopidine (TP) and cilostazol (OPC-13013; in the following briefly called CS), a new antithrombotic agent on platelet functions ex vivo. Nine patients with cerebral thrombosis were enrolled in this study. Patients were given each of the three drugs for one week in a complete cross-over design according to a randomization schedule, followed by a wash-out period with a placebo for one week. It was found that CS and TP significantly inhibited platelet aggregation induced by ADP. Collagen- and arachidonic acid-induced platelet aggregation was all inhibited by CS, TP and ASA. Duncan's multiple range test to compare the anti-platelet effects of the three drugs revealed that: CS > ASA and TP > ASA in inhibiting ADP-induced platelet aggregation and CS > TP and ASA > TP in inhibiting arachidonic acid-induced platelet aggregation. These results may suggest that CS is superior to ASA and TP in inhibiting platelet aggregation ex vivo.",
author = "Y. Ikeda and M. Kikuchi and H. Murakami and K. Satoh and Mitsuru Murata and K. Watanabe and Y. Ando",
year = "1987",
language = "English",
volume = "37",
pages = "563--566",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "5",

}

TY - JOUR

T1 - Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study

AU - Ikeda, Y.

AU - Kikuchi, M.

AU - Murakami, H.

AU - Satoh, K.

AU - Murata, Mitsuru

AU - Watanabe, K.

AU - Ando, Y.

PY - 1987

Y1 - 1987

N2 - A randomized double-blind cross-over study was conducted to determine the inhibitory effects of acetylsalicylic acid (ASA), ticlopidine (TP) and cilostazol (OPC-13013; in the following briefly called CS), a new antithrombotic agent on platelet functions ex vivo. Nine patients with cerebral thrombosis were enrolled in this study. Patients were given each of the three drugs for one week in a complete cross-over design according to a randomization schedule, followed by a wash-out period with a placebo for one week. It was found that CS and TP significantly inhibited platelet aggregation induced by ADP. Collagen- and arachidonic acid-induced platelet aggregation was all inhibited by CS, TP and ASA. Duncan's multiple range test to compare the anti-platelet effects of the three drugs revealed that: CS > ASA and TP > ASA in inhibiting ADP-induced platelet aggregation and CS > TP and ASA > TP in inhibiting arachidonic acid-induced platelet aggregation. These results may suggest that CS is superior to ASA and TP in inhibiting platelet aggregation ex vivo.

AB - A randomized double-blind cross-over study was conducted to determine the inhibitory effects of acetylsalicylic acid (ASA), ticlopidine (TP) and cilostazol (OPC-13013; in the following briefly called CS), a new antithrombotic agent on platelet functions ex vivo. Nine patients with cerebral thrombosis were enrolled in this study. Patients were given each of the three drugs for one week in a complete cross-over design according to a randomization schedule, followed by a wash-out period with a placebo for one week. It was found that CS and TP significantly inhibited platelet aggregation induced by ADP. Collagen- and arachidonic acid-induced platelet aggregation was all inhibited by CS, TP and ASA. Duncan's multiple range test to compare the anti-platelet effects of the three drugs revealed that: CS > ASA and TP > ASA in inhibiting ADP-induced platelet aggregation and CS > TP and ASA > TP in inhibiting arachidonic acid-induced platelet aggregation. These results may suggest that CS is superior to ASA and TP in inhibiting platelet aggregation ex vivo.

UR - http://www.scopus.com/inward/record.url?scp=0023195289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023195289&partnerID=8YFLogxK

M3 - Article

C2 - 2956957

AN - SCOPUS:0023195289

VL - 37

SP - 563

EP - 566

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 5

ER -